Wire · opportunities
FDA Grants Breakthrough Therapy Status to GLM101 for PMM2-CDG
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
The FDA has granted Breakthrough Therapy designation to GLM101 for treating PMM2-CDG, a rare congenital disorder. The phase 2b POLAR trial measuring ataxia outcomes via ICARS is expected to report data in Q4 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech startup focusing on rare neurological disorders now sees accelerated FDA engagement and a clearer pathway for PMM2-CDG treatment approval. Use this window to align clinical and regulatory plans tightly around the 2026 POLAR data readout.
◆ Coverage
1 source · 23 Sep 2026
◆ Related on Wire
◆ Topics
Biotechfdabreakthrough-therapyrare-diseaseclinical-trialpmmd-cdg